Featured Research

from universities, journals, and other organizations

Pre-treatment Blood Test Could Guide Lung Cancer Therapy

Date:
June 6, 2007
Source:
Vanderbilt University Medical Center
Summary:
Scientists have developed a new pre-treatment blood test that predicts which non-small-cell lung cancer patients will live longer when they are treated with certain targeted cancer therapies (Iressa, Tarceva). The mass spectrometry-based test may allow physicians to select the most beneficial therapy for each lung cancer patient, a step forward in the era of personalized medicine.

A multi-center team, led by Vanderbilt-Ingram Cancer Center investigators, has discovered a "signature" of proteins in the blood that predicts which non-small-cell lung cancer patients will live longer when they are treated with certain targeted cancer therapies.

The findings, published June 6 in the Journal of the National Cancer Institute, could one day help physicians decide which lung cancer patients to treat with drugs known collectively as EGF receptor tyrosine kinase inhibitors, a step forward in the era of personalized medicine.

"There's a real clinical need to identify which patients will benefit from targeted therapies," said David Carbone, M.D., Ph.D., Harold L. Moses Professor of Cancer Research at Vanderbilt-Ingram and the senior author of the study. "If our findings are confirmed, we will be able to use a simple and inexpensive blood test to select the most beneficial therapy for each patient."

Targeted cancer therapies are the newest generation of anti-cancer drugs. In contrast to traditional chemotherapy, targeted therapies affect proteins and signaling pathways that are selectively activated in certain malignant cells and not in normal cells. But this selectivity makes these therapies effective only for the subset of patients whose tumors are "driven" by the targeted pathways.

The drawbacks of treating every patient with a targeted therapy include the expense of these drugs, the delay -- for those who do not respond -- in initiation of effective therapy, and the possibility that some patients will be harmed by the targeted therapy.

In the case of the EGF receptor tyrosine kinase inhibitors (TKIs) gefitinib (Iressa) and erlotinib (Tarceva), studies have demonstrated a survival benefit for 30 to 40 percent of lung cancer patients, but there has been no method for identifying these patients prior to treatment, Carbone said.

Investigators at Vanderbilt-Ingram, the University of Colorado in Aurora, Colo., and Biodesix Inc. in Steamboat Springs, Colo., with worldwide collaborators providing patient samples, set out to determine if a protein profile in the peripheral blood could predict clinical benefit -- measured in terms of patient survival -- to EGF receptor TKIs.

Using mass spectrometry, the researchers analyzed pre-treatment blood samples from 139 patients who had been treated with gefitinib (three patient cohorts in Italy and Japan), identified a pattern of eight proteins that was correlated with survival, and developed a prediction algorithm.

They then tested the algorithm in two additional groups of patients -- 67 gefitinib-treated patients in Italy and 96 erlotinib-treated patients in a U.S. Eastern Cooperative Oncology Group protocol. At the time of the mass spectrometry analysis and classification, the researchers were "blind" to the survival status of the patients.

"We classified the patients as being either likely to benefit ("good") or not likely to benefit ("poor") from the TKIs," Carbone said.

The method was highly successful in predicting a survival benefit. In the gefitinib-treated group, patients classified as "good" had a median survival of 207 days whereas those classified as "poor" had a median survival of 92 days. In the erlotinib-treated group, median survivals for "good" and "poor" groups were 306 and 107 days, respectively. The fact that the signature, which was developed from gefitinib-treated patients, also accurately predicted a survival benefit for erlotinib-treated patients buoys Carbone's confidence in the algorithm, he said, since these two drugs share a common mechanism of action.

The method was not prognostic -- it did not predict a survival benefit in three different control groups of patients treated with either chemotherapy or surgery alone.

The investigators are currently working with the Eastern Cooperative Oncology Group to develop a prospective national phase III trial that will test the prediction method's clinical benefit in lung cancer patients who are just beginning treatment for advanced disease.

"This is a convincing set of data from multiple institutions and multiple cohorts of patients, and we're excited to test the prediction algorithm in a prospective way," Carbone said. "If it holds up, we will be able to separate patients into two groups -- one that would benefit more from chemotherapy and the other from targeted TKIs -- and treat them accordingly. The overall survival of the whole group of patients would be better by virtue of this biomarker-based test."

The research was supported by the National Cancer Institute's Specialized Programs of Research Excellence (SPOREs) in Lung Cancer and cancer center core grants to Vanderbilt-Ingram and the University of Colorado.


Story Source:

The above story is based on materials provided by Vanderbilt University Medical Center. Note: Materials may be edited for content and length.


Cite This Page:

Vanderbilt University Medical Center. "Pre-treatment Blood Test Could Guide Lung Cancer Therapy." ScienceDaily. ScienceDaily, 6 June 2007. <www.sciencedaily.com/releases/2007/06/070605185708.htm>.
Vanderbilt University Medical Center. (2007, June 6). Pre-treatment Blood Test Could Guide Lung Cancer Therapy. ScienceDaily. Retrieved October 21, 2014 from www.sciencedaily.com/releases/2007/06/070605185708.htm
Vanderbilt University Medical Center. "Pre-treatment Blood Test Could Guide Lung Cancer Therapy." ScienceDaily. www.sciencedaily.com/releases/2007/06/070605185708.htm (accessed October 21, 2014).

Share This



More Health & Medicine News

Tuesday, October 21, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

CDC Revamps Ebola Guidelines After Criticism

CDC Revamps Ebola Guidelines After Criticism

Newsy (Oct. 21, 2014) The Centers for Disease Control and Prevention have issued new protocols for healthcare workers interacting with Ebola patients. Video provided by Newsy
Powered by NewsLook.com
First-Of-Its-Kind Treatment Gives Man Ability To Walk Again

First-Of-Its-Kind Treatment Gives Man Ability To Walk Again

Newsy (Oct. 21, 2014) A medical team has for the first time given a man the ability to walk again after transplanting cells from his brain onto his severed spinal cord. Video provided by Newsy
Powered by NewsLook.com
CDC Issues New Ebola Guidelines for Health Workers

CDC Issues New Ebola Guidelines for Health Workers

Reuters - US Online Video (Oct. 21, 2014) The U.S. Centers for Disease Control and Prevention has set up new guidelines for health workers taking care of patients infected with Ebola. Linda So reports. Video provided by Reuters
Powered by NewsLook.com
'Cadaver Dog' Sniffs out Human Remains

'Cadaver Dog' Sniffs out Human Remains

AP (Oct. 21, 2014) Where's a body buried? Buster's nose can often tell you. He's a cadaver dog, specially trained to find human remains and increasingly being used by law enforcement and accepted in courts. These dogs are helping solve even decades-old mysteries. (Oct. 21) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins